The transcriptional activity of estrogen receptors (ERs) can be regulated by ligands, as well as agents such as dopamine which stimulate intracellular signaling pathways able to communicate with these receptors. We examined the ability of SKF-82958 (SKF), a previously characterized full dopamine D1 receptor agonist, to stimulate the transcriptional activity of ERα and ERβ. Treatment of HeLa cells with SKF-82958 stimulated robust ERα-dependent transcription from an ERE-E1b-CAT reporter in the absence of estrogen and this was accompanied by increased receptor phosphorylation. However, induction of ERβ-directed gene expression under the same conditions was negligible. In our cell model, SKF treatment did not elevate cAMP levels nor enhance transcription from a cAMP-response element (CRE)-linked reporter. Control studies revealed that SKF-82958, but not dopamine, competes with 17β-estradiol (E2) for binding to ERα or ERβ with comparable relative binding affinities. Therefore SKF-82958 is an ERα-selective agonist. Transcriptional activation of ERα by SKF was more potent than expected from its relative binding activity, and further examination revealed that this synthetic compound induced expression of an AP-1 target gene in a TPA response element (TRE)-dependent manner. A putative TRE site upstream of the estrogen response element and the receptor's amino-terminal domain contributed to, but were not required for, SKF-induced expression of an ERα-dependent reporter gene.
INTRODUCTION
The effects of estrogens are mediated by the products of two separate genes; one for estrogen receptor-α (ERα) 1 and another for ERβ. Both are members of the nuclear receptor superfamily of ligandactivated transcription factors. The mechanisms by which ERs activate target gene expression in response to estrogen signaling have been the subject of intense investigation since their respective cDNAs were cloned (1, 2) . Owing to the relatively recent identification of ERβ, the bulk of our knowledge regarding the genomic effects of estrogens is derived from ERα studies. For instance, upon binding to 17β-estradiol (E2), ERα undergoes a series of biochemical alterations including increased phosphorylation and conformational changes as well as the receptor's homodimerization and binding to its target DNA sequence, the estrogen response element [ERE; refs. (3) (4) (5) ]. ERβ also undergoes conformational changes in response to ligand binding (6, 7) , and is phosphorylated in vivo (8) . With respect to DNA binding, ERβ binds to the same consensus ERE that ERα does, although the latter receptor has an ~4-fold higher affinity for this DNA sequence in comparison to ERβ (9, 10) .
While many aspects of the regulation of ERα and ERβ transcriptional activity are quite similar (e.g. both bind to EREs and activate transcription in response to E2 binding), a number of differences between these receptors have been noted. For instance, on ERE-containing reporters, ligands such as 4-hydroxytamoxifen exert partial agonist activity on ERα, but act as ERβ antagonists (11) . This is likely related to differences in the poorly conserved structure and function of the hormone-independent activation function-1 (AF-1) domain which is located in the amino-termini of these receptors (11) (12) (13) .
The carboxy-terminal AF-2 domain is hormone-dependent, reflecting the ability of agonists to bind to the receptor's ligand binding domain and induce a conformational change that creates a binding site for coactivators such as steroid receptor coactivator-1 (SRC-1) and its related family members (14, 15) .
Intriguingly, this domain is only ∼60% conserved between ERα and ERβ, and small differences in the affinity of these two receptors for ligands such as genistein and 16α-bromo-17β-estradiol have been demonstrated (16, 17) . Although several contexts exist whereby the transcriptional activity of ERα is (36) . The mechanisms by which the dopaminergic cell signaling pathway communicates with ERα are not well defined, but it is presumed that increased ERα phosphorylation contributes to this process. In this regard, it is interesting to note that cAMP signaling pathways stimulate ERα transcriptional activity and phosphorylation (38, 39) . The chicken PR is also ligand-independently activated by treatment of cells with dopamine or agents that increase intracellular cAMP levels (31, 40) . However, cAMP activation of PR-dependent transcription is not accompanied by increased receptor phosphorylation, but rather by an increase in the phosphorylation of the SRC-1 coactivator with which the receptor interacts to stimulate gene expression (41, 42) . Taken together, the data support a model in which dopamine and cAMP signaling pathways stimulate gene expression in a receptor-specific manner.
Alterations in the biology of dopamine and its receptors play an important role in a number of human diseases, such as Parkinson's disease, as well as contribute to the reward seeking behaviors associated with cocaine abuse (43) (44) (45) . The molecular mechanisms of dopamine and dopamine receptor action have therefore been extensively studied, and these efforts have been aided by the identification of high affinity and potent ligands for dopamine receptors. One such compound, SKF-82958 (SKF), is a full dopamine D1-subtype selective receptor agonist with greater potency than dopamine (46, 47) . SKF has also been shown to stimulate the transcriptional activity of ERα in SK-N-SH neuroblastoma and MCF-7 breast cancer cells (27, 37) . We therefore used SKF-82958 to determine the ability of dopaminergic signaling pathways to regulate ERβ transcriptional activity. We observed that this D1 receptor-selective agonist stimulated the transcriptional activity of ERα, but had negligible agonist activity for ERβ. We also found that SKF-82958 stimulates phosphorylation of ERα to an extent similar to that observed for E2.
However, SKF-82958 competed with E2 for binding to the receptor, suggesting that it exerts at least some of its effects on ERα transcriptional activity as an ERα agonist. Stimulation of ERα transactivation was greater than that anticipated from its relative binding affinity for ERα, and we therefore examined the ability of SKF-82958 to stimulate intracellular signal transduction pathways. While SKF-82958 did not increase cAMP production, it did stimulate pathways leading to activation of AP-1, a transcription factor known to functionally interact with many steroid receptors (3), and we therefore examined the contribution of AP-1 to SKF-induced ERα transcriptional activity. These studies provide novel information on the ability of a compound to simultaneously stimulate the activity of two transcription factors and in so doing produce robust stimulation of gene expression through a combinatorial response within the cell. International (Natick, MA) as were dopamine and the synthetic D1 receptor agonist, SKF-82958. All other chemicals were reagent grade.
EXPERIMENTAL PROCEDURES Chemicals

Plasmids
The mammalian expression vectors for wild type human ERα (pCMV 5 -hERα) and its corresponding phosphorylation mutants (S104A/S106A/S118A, S118A and S167A) have been described previously (39) as have the plasmids for human ERβ [pCMV 5 To prepare reagents for adenovirus-mediated transfections, replication-deficient adenovirus dl312
was propagated and covalently modified with poly-L-lysine by the method of Cristiano et al. (62) modified as described previously (61) . CsCl-purified fractions of the modified virus were stored at -80 C until use. Adenovirus-DNA complexes were prepared by adding the lysine-modified adenovirus to plasmid DNA and subsequently incubating with a 200-fold molar excess of poly-L-lysine (M r 18-20,000).
The adenovirus-DNA-lysine complex was then added to the cells at a virus to cell multiplicity of infection of 500:1. After incubation for 2 h, the medium was replaced with phenol-red-free DMEM supplemented with 5% sFBS. Hormones and/or other treatments, as indicated, were added to the cells 4 h later, and the cells were then harvested 24 h thereafter.
Assays of reporter gene expression were performed on cell extracts prepared by lysing cells by rapid freeze-thaw or addition of lysis buffer (Promega). CAT activity was measured by a phase-extraction method utilizing [ 3 H]chloramphenicol (NEN, Boston, MA) and butyryl-coenzyme A (Pharmacia) as substrates (30, 63) . Luciferase activity was measured using the Luciferase Assay System (Promega).
Duplicate samples were measured in each experiment and data are presented as the average ± SEM of at least three experiments normalized to protein content measured by BioRad protein assay reagent or β-galactosidase.
Relative Binding Affinity Assays
Relative receptor binding affinities were determined in vivo as described previously (64) . Briefly, the adenovirus-mediated DNA transfer procedure was used to transfect HeLa cells with 0.25 µg/well of the appropriate expression vector (pCMV 5 -hERα or pCMV 5 -hERβ). Twenty-four hours thereafter, media was aspirated from wells, and replaced with phenol-red-free DMEM containing 5% sFBS, ∼1 pmol 
RESULTS
SKF-82958 activation of ERα α α α-dependent gene transcription
As previously reported (37), the dopamine D1-selective agonist SKF-82958 (±-6-chloro-7,8- 
SKF-82958 binds to ERα α α α and ERβ β β β, but preferentially activates ERα α α α
In order to determine whether SKF-82958 could bind to ERs, whole cell competitive hormone binding assays were performed in HeLa cells transfected with expression vectors for either ERα or ERβ. (Fig. 3B) . The ability of SRC family and CBP coactivators to enhance SKF-induced ERα transactivation was also examined. Each was able to significantly enhance the transcriptional activity of ERα (Fig. 3C) ,
suggesting that SKF-82958 binding to the receptor allows coactivator-ERα functional interactions.
Characterization of Flag-tagged ERα α α α
Activation of human ERα by E2 is accompanied by increased receptor phosphorylation (39, 66) . In order to determine if SKF-82958 alters the biochemical properties of ERα, the phosphorylation status of the receptor was assessed in HeLa cells treated with SKF-82958 versus E2. First, an expression vector was constructed for Flag-ERα so that distinct antibodies could be used for immunoprecipitation (anti-ERα) and for receptor quantitation by Western blot analysis (anti-Flag). To demonstrate that the M2 antibody against the Flag epitope reacted with only Flag-ERα, cell lysates were prepared from HeLa cells transfected with either pJ3-Flag-hERα or empty parent vector (pJ3Ω), and subjected to Western blot analysis. The M2 antibody detected an appropriately sized band in HeLa cells transfected with pJ3-FlaghERα, but not in mock-transfected cells (Fig. 4A) . In a separate experiment, the hERα antibody, H222, was used to ensure that the protein encoded by the pJ3-Flag-ERα expression vector was immunoreactive with ERα antibodies. As expected, Western blot analysis demonstrated that the Flag-ERα migrated with a slightly lower mobility than wild type ERα (Fig. 4B) . (Fig. 5A) . As expected, the phosphorylation level of Flag-ERα isolated from cells treated with E2 was also significantly increased in comparison to basal levels. When protein levels were taken into account, the data averaged from 4 experiments indicate that E2 increased ER phosphorylation by 1.7 ± 0.4-fold, while SKF treatment increased ER phosphorylation by 2.2 ± 0.4-fold (Fig. 5B) .
To determine if any of the known ER serine phosphorylation sites are critical for activation of the receptor by the SKF signal transduction pathway(s), the ability of this putative ligand to stimulate the activity of ER phosphorylation site mutants was assessed (39, 66, 67) . Although SKF-82958 was able to stimulate the transcriptional activity of each amino-terminal phosphorylation mutant, activation of S118A (2.7 ± 0.3-fold) and S104A/S106A/S118A ERα (2.5 ± 0.5-fold) ERα mutants was decreased relative to the ability of this compound to activate either wild type (4.5 ± 0.3-fold) or the S167A (4.7 ± 0.2-fold) mutant. These data are consistent with the effects of these mutations on E2-dependent activity (39, 66 and our data), and suggest that serines 118 and possibly 104/106 may contribute to, but are not required for, activation of ERα in response to SKF-82958 treatment.
Functional domains of ERα α α α required for SKF-82958 activation
To more generally test the regions of ER required for SKF activation, the ability of this compound to stimulate the transcriptional activity of a series of ER mutants (Fig. 6A) was tested. Mutation of the AF-2 domain (D538A/E542A/D545A) in the ERα-3x mutant reduced the ability of E2 and SKF to stimulate ER activity by ∼64% and ∼78%, respectively, suggesting that the C-terminal AF-2 domain contributes to both mechanisms of activation (Fig. 6B ). An ER mutant lacking the ligand binding and F domains constructs in which the putative TRE site was eliminated by deletion (∆Nde-Eco) or point (mTRE) mutagenesis (Fig. 8A) . The latter point mutant was examined to rule out the possibility that the deletion mutant introduced structural perturbations or removed other cryptic DNA sequences from the reporter that might alter transcriptional responses. As shown in Fig. 8B , significant CAT expression was induced by treatment with E2 or SKF-82958 from either the intact or mutant forms of the ERE-E1b-CAT reporter gene. Moreover, the fold-induction by E2 was similar for the three reporter genes, whereas SKF-82958 induction of CAT gene expression was diminished by ∼23% and ∼28%, when the TRE was deleted or mutated, respectively. The similarity in SKF-82958 effect on gene expression between the reporters generated by deletion versus site directed-mutagenesis is consistent with the interpretation that it is the upstream TRE element, rather than some other element or structural alteration, that contributes to the magnitude of SKF-82958-induced ERα transactivation under these conditions. Moreover, in experiments in which a ClaI to BglI linear fragment of the ERE-E1b-Luc plasmid encompassing just the ERE, E1b and luciferase sequences was transfected into HeLa cells with an ERα expression plasmid, SKF stimulation of ERα activity relative to E2 was 50% the level seen for unaltered (circular) target gene (data not shown).
Taken together, these results support the hypothesis that TRE elements in reporter plasmids may enhance, but are not required for, induction of ERα-dependent gene transcription by multifunctional ligands such as SKF-82958.
Since TRE-dependent activity significantly enhanced SKF activation of ERα-dependent gene expression, and since c-Jun has been shown to bind to the amino-terminus of ERα (57), we wanted to ensure that the LBD and AF-2 could support SKF activation of gene expression in the absence of AF-1.
We therefore examined the ability of ERα-179C to be activated by SKF-82958 in the absence of the upstream TRE. As shown in Fig. 8C , loss of the reporter's TRE site and the receptor's AF-1 domain significantly compromises the ability of SKF-82959 to activate ERα-dependent gene expression, consistent with the interpretation that both the AF-1 and TRE contribute to SKF-induced transcriptional activity. Taken together, these data suggest that SKF-82958 on its own is a weak ERα agonist and that the robust activation seen with full-length receptor is a result of the synergistic activation of ERα and cellular factors, such as c-Jun or c-Fos, that can bind to the TRE (60).
Effect of AP-1 overexpression on ERα α α α transactivation by SKF-82958
The above observations suggest that transcription factors able to interact with the TRE binding site and not through binding to ERα (Fig. 9A) . Fos overexpression resulted in only very modest increases in the effects of E2 and SKF-82958, with no significant effect on basal activity (Fig. 9B) . The result from the combination of c-Jun with c-Fos was similar to that of c-Jun alone (Fig. 9C) . In all experiments performed with the ERE-E1b-CAT(∆Nde-Eco) reporter construct lacking the TRE, no significant increases in transcriptional activation were induced by AP-1 overexpression (Figs. 9, A-C), suggesting that the TRE binding site was required for strong AP-1 effects.
DISCUSSION
The relatively high concentration of SKF-82958 required to achieve ERα transcriptional activity in comparison to dopamine D1 receptor activation suggested that this compound was an ERα agonist, and our relative binding affinity analyses demonstrated that SKF competed with E2 for binding to either ERα or ERβ. However, the results obtained in this study demonstrate that SKF-82958 stimulates the transcriptional activity of ERα, but not ERβ, and therefore SKF-82958 is an ERα selective agonist.
Intriguingly, our studies also demonstrated that SKF stimulates the transcriptional activity of AP-1, and provides evidence that in the appropriate promoter context activation of target gene expression by SKF is the combinatorial result of AP-1 and ERα activation. Understanding the role of AP-1 in SKF-dependent ERα transactivation is particularly important given the ability of SKF to activate both transcription factors. In so doing, the results of these studies provide an example of how other transcription factors can seemingly enhance the potency of weak ER ligands.
Although SKF-82958 is a full agonist of dopamine D1 receptors, it failed to stimulate increases in intracellular cAMP, nor was it able to stimulate CRE-dependent gene expression in our HeLa cells. We had previously shown that dopamine treatment of HeLa cells increased cAMP levels in a dose-dependent manner in vitro (30) , and the inability of SKF to do so here was unexpected. Although SKF-induction of cAMP in SK-N-SH cells had not been characterized, the protein kinase A inhibitor, H89, partially blocked ERα transactivation by SKF-82958 (37), suggesting that a cAMP signaling transduction pathway was playing a role in these cells. Similarly, H89 reduced SKF induction of ER transcription activity in MCF-7 cells (27) . These reports are consistent with the ability of SKF to stimulate adenylate cyclase and cAMP production via the dopamine D1 receptor (46, 47) , and it is possible that in these cell models ERα transactivation by SKF is at least partially cAMP/protein kinase A dependent and/or that H89 is inhibiting the activity of other signaling pathways able to crosstalk with ERα or AP-1. Indeed, while H89 effectively inhibits protein kinase A, it also blocks the activity of other kinases including protein kinase B (Akt) and mitogen-and stress-activated protein kinase-1 (72).
The inability of SKF to stimulate ERβ transcriptional activity is unlikely to be due to the minor differences in the relative binding affinities of this compound for ERα and ERβ. A large number of naturally-occurring substances, as well as pharmacological and environmental agents, bind to ERs (16, 17) . The crystal structures of receptors complexed with E2, diethylstilbestrol, raloxifene or 4-hydroxytamoxifen, and molecular modeling studies suggest that binding of a phenolic group to the A-ring binding pocket of the receptors' ligand binding domains is a common feature (14, (73) (74) (75) . While SKF-82958 does not possess a simple phenolic ring characteristic of many ER ligands (Fig. 1A) , it does have a hydroxy-phenolic ring with a large, bulky chlorine substituent. Based on the ability of C(2) substituted derivatives of E2 and estrone (2-hydroxyestradiol and 2-hydroxyestrone, respectively) to have severely reduced relative binding affinities for ERs (16, 17) and the chlorine atom on SKF-82958, it was unexpected that SKF would inhibit E2 occupancy of the ligand binding pocket. This result is perhaps even more surprising in view of the inability of dopamine to bind to ERα or ERβ, since dopamine also possesses a hydroxy-phenol ring. However, it is possible that the remainder of the dopamine molecule is of insufficient size to interact with other regions of the ligand binding pocket required for high affinity binding. It will be interesting to determine whether chemical derivatives of SKF-82958 can be generated with increased receptor affinity.
There is significant interest in identifying ER subtype selective agonists and antagonists, and several investigators have made progress in identifying and characterizing such compounds. These include a cisdiethyl-substituted tetrahydrochrysene which has a 4-fold preferential binding affinity for ERβ and is an ERα agonist and complete ERβ antagonist (76) , and a methoxychlor metabolite that inhibits estrogeninduced ERβ activity, yet stimulates the transcriptional activity of ERα (77) . Potency selective agonists have also been identified such as pyrazole, which has a 120-fold greater potency for stimulating ERα activity in comparison to ERβ (76) , and A-ring reduced metabolites of the 19-nor synthetic progestins, norethisterone and Gestodene, which have at least a 100-fold greater potency for ERα in comparison to ERβ transcriptional activity (78) . In addition to these compounds, differences in the ability of steroidal derivatives and non-steroidal phytoestrogens to bind to ERα and ERβ have also been reported (16, 17) .
Moreover, the differences in the relative agonist and antagonistic activity of several of these novel compounds has been found to correlate with changes in the conformation of the receptors and their ability to bind to SRC family coactivators (79) . For instance, the ERα agonist propyl pyrazole triol induces an agonistic conformational change in ERα and promotes interaction of this receptor with SRC-1, GRIP1
and ACTR, but does not promote interaction of ERβ with these coactivators. We have demonstrated that SRC family coactivators as well as the general coactivator CBP can enhance SKF-induced ERα transactivation and this is consistent with SKF inducing a conformational change able to promote ERα-coactivator interactions.
Having established that SKF-82958 is an ERα-selective agonist, we examined the mechanism(s) by 
